Loading patent…
OwnerDavid Frederick Callen, Gabriel Kremmidiotis +3inventors
InventorsDavid Frederick Callen, Gabriel Kremmidiotis, Scott Whitmore, Alison Gardner, Jason Powell
Estimating the term…
A method for the diagnosis of a predisposition thereto, in a patient, comprising the steps of: (1) establishing the level of expression of a gene selected from the group consisting of PR domain containing 7 protein (PRDM7), CDT1 DNA replication factor (CDT1), charged multivesicular body protein 1/chromoatin modifying protein 1 (CHMP1), BTG3 associated nucleoprotein (BANP), BNO224, BNO36, BNO34, BNO208, BNO230 and BNO44; and (2) comparing expression of the gene to a baseline established from expression in normal tissue controls; wherein substantial variance from the baseline indicates that the patient is susceptible to cancer.
A method for the diagnosis of a predisposition to cancer, in a patient, comprising the steps of:
A method for determining whether a human tissue is predisposed to a neo-plastic transformation, comprising determining whether in a cell from the tissue a nucleic acid molecule selected from the group consisting of PRDM7, CDT1, CHMP1, BANP, BNO224, BNO36, BNO34, BNO208, BNO230 and BNO44 is absent, present in a mutant form or down-regulated through epigenetic mechanisms.
A mutant form of PRDM7, CDT1, CHMP1, BANP, BNO224, BNO36, BNO34, BNO208, BNO230 and BNO44 in which the tumour suppressor activity of the gene is compromised.
An isolated nucleotide molecule selected from the group consisting of nucleotide molecules having the sequence set forth in SEQ ID NO:5;
An isolated polypeptide having the amino acid sequence set forth in any one of the group consisting of SEQ ID NO:6;
A polypeptide encoded by a gene comprising a nucleotide sequence set forth in any one of the group consisting of SEQ ID NO:5;
An antibody to a polypeptide having an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26.
Use of a nucleotide molecule having the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:25 in the diagnosis of cancer or in establishing the prognosis of a patient diagnosed with cancer.
Use of a polypeptide having an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26 in the diagnosis of cancer or in establishing the prognosis of a patient diagnosed with cancer.
A microarray comprising oligonucleotides or longer fragments derived from any one or more of the genes PRDM7, CDT1, CHMP1, BANP, BNO224, BNO36, BNO34, BNO208, BNO230 and BNO44.
A method of treating or inhibiting breast cancer in a patient in need of such treatment comprising the steps of administering to said patient a vector capable of expressing a gene selected from the group consisting of PRDM7, CDT1, CHMP1, BANP, BNO224, BNO36, BNO34, BNO208, BNO230 and BNO44.
A method of treating or inhibiting cancer in a patient in need of such treatment, said method comprising administering to said patient a compound which increases expression or activity of a gene selected from the group consisting of PRDM7, CDT1, CHMP1, BANP, BNO224, BNO36, BNO34, BNO208, BNO230 and BNO44.
Use of a nucleotide molecule having the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:25 in the treatment of cancer through gene therapy.
Use of a polypeptide having the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26 in the treatment of cancer.
A genetically modified non-human animal in which a gene selected from the group consisting of PRDM7, CDT1, CHMP1, BANP, BNO224, BNO36, BNO34, BNO208, BNO230 and BNO44 has been inactivated by knockout deletion.
A method of screening for candidate drugs which restore tumour suppressor activity, comprising the steps of:
A compound which increases expression or activity of a gene selected from the group consisting of PRDM7, CDT1, CHMP1, BANP, BNO224, BNO36, BNO34, BNO208, BNO230 and BNO44.
A cell comprising an expression vector capable of expressing PRDM7, CDT1, CHMP1, BANP, BNO224, BNO36, BNO34, BNO208, BNO230 and BNO44.
A cell transformed with a nucleotide molecule having the sequence set forth in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:25.
A pharmaceutical composition comprising any one or more of the genes selected from the group consisting of PRDM7, CDT1, CHMP1, BANP, BNO224, BNO36, BNO34, BNO208, BNO230 and BNO44, active fragments thereof, their expression products and antibodies to their expression products, and an inert carrier.
Dependencies are inferred from the claim text.